Optimizing the Use of Novel Agents for the Treatment of Leukemia
There have been several significant advances related to the treatments of CML, AML, and ALL. Innovative therapies that are recently FDA approved or in the later stages of clinical development are revolutionizing options for effective care in these patients. These rapid advancements and novel therapeutic options for multiple hematologic malignancies require clinicians to have a heightened awareness in order to optimize the management of leukemia and improve patient outcomes.
Optimizing the Use of Novel Agents for the Treatment of Leukemia will guide clinicians in the integration of new data into clinical practice through case-based discussions and an emphasis on the importance of patient communication. This educational initiative is designed to increase awareness of novel treatment options and, ultimately, allow clinicians to appropriately incorporate new data into the management of their leukemia patients.
- Increase awareness of the importance of long-term safety with BCR-ABL TKIs in CML management for individualized treatment based on patient history and any comorbidities
- Improve awareness of FDA-approved agents and/or therapies under development for the treatment of AML and ALL
- Incorporate FDA-approved agents and therapies under development into treatment paradigms for AML and ALL
This activity is intended for community-based hematologists/oncologists and other clinicians involved in the care of patients with leukemia.
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Nurses: Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Physicians: The Potomac Center for Medical Education designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the CME accreditation of this program, please email: email@example.com.
Nurses: This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
For information about the CNE accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
B. Douglas Smith, MD
Professor of Oncology
Johns Hopkins University, School of Medicine
Jonathan Webster, MD
Instructor of Oncology
Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control content of a continuing medical education program provided by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards of Commercial Support in advance of delivery of the activity to learners.
Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.). Please email email@example.com at least 5 days prior to the program.
Jointly provided by the Potomac Center for Medical Education and Rockpointe Oncology
Jointly provided by Global Education Group and Rockpointe Oncology
This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer.
Utah Program Faculty
Satish Shanbhag, MBBS, MPH, FACP
Assistant Professor of Medicine and Oncology
Johns Hopkins University School of Medicine
Clinical Director of Hematology
Johns Hopkins Bayview Medical Center
Chicago Program Faculty
Jonathan Webster, MD
Instructor of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins